Chimeric antigen receptor (CAR) T cells have been approved for use in patients with B cell
malignancies or relapsed and/or refractory multiple myeloma, yet efficacy against most solid …

The introduction and the unexpected efficacy of checkpoint inhibitors (CPI) and more
recently of chimeric antigen receptor T cells (CAR T-cells) in the treatment of malignant …

Adoptive T cell transfer (ACT) therapies suffer from a number of limitations (eg, poor control
of solid tumors), and while combining ACT with cytokine therapy can enhance effectiveness …

Cancer receives enduring international attention due to its extremely high morbidity and
mortality. Immunotherapy, which is generally expected to overcome the limits of traditional …

The promise of tumor immunotherapy to significantly improve survival in patients who are
refractory to long-standing therapies, such as chemotherapy and radiation, is now being …

Background Target antigen (Ag) loss has emerged as a major cause of relapse after
chimeric antigen receptor T (CART)-cell therapy. We reasoned that the combination of CART …

Recent studies suggest that highly activated, polyfunctional CD4+ T cells are incredibly
effective in strengthening and sustaining overall host antitumor immunity, promoting tumor …

Despite the tremendous clinical successes recorded in the landscape of cancer therapy,
tumor heterogeneity remains a formidable challenge to successful cancer treatment. In …

Tissue-resident memory T (TRM) cells mediate potent local innate and adaptive immune
responses and provide long-lasting protective immunity. TRM cells localize to many different …

Background Despite recent advances, there is an urgent need for agents targeting HER2-
expressing cancers other than breast cancer. We report a phase I study (NCT01730118) of a …